FDA Grants Landmark Approval for REVTORPYK: A New Standard for PIK3CA Wild-Type Breast Cancer
- Badari Andukuri
- 1 day ago
- 2 min read
The U.S. Food and Drug Administration (FDA) has approved Celcuity’s REVTORPYK (gedatolisib) for the treatment of HR+/HER2- metastatic breast cancer patients who do not possess a PIK3CA mutation.
As the first therapy capable of inhibiting all class I PI3K isoforms (α, β, δ, γ) in conjunction with both mTORC1 and mTORC2 complexes, REVTORPYK introduces a novel mechanism of action for a patient population that accounts for approximately 42% of all HR+/HER2- diagnoses.
Key Regulatory Proposals
The approval follows the clinical outcomes demonstrated in the Phase 3 VIKTORIA-1 trial.
Data indicated that patients receiving a triplet regimen of REVTORPYK, palbociclib, and fulvestrant experienced a 76% reduction in the risk of disease progression or death
The median progression-free survival (PFS) of 9.3 months compared to 2.0 months for those on fulvestrant alone.
A doublet regimen, combining REVTORPYK with fulvestrant, also showed significant efficacy with a 67% reduction in disease progression or death risk and a median PFS of 7.4 months.
Furthermore, the objective response rate (ORR) reached 32% for the triplet and 28% for the doublet, substantially outperforming the 1% ORR observed in the control group.
Celcuity expects a commercial market release in late Q3 2026, supported by an expanded access program currently available to eligible patients.
Additionally, the company intends to submit a supplemental New Drug Application (sNDA) in Q3 2026, targeting the PIK3CA-mutated cohort following data disclosures at the 2026 ASCO Annual Meeting.
Market & Clinical Implications
The introduction of REVTORPYK is poised to drive a shift in the site-of-care landscape.
Due to the therapeutic complexity and intensive patient monitoring requirements associated with dual PI3K/mTOR inhibition, clinical utilization is expected to concentrate within large hospital systems and academic centers.
Industry Context
The approval of REVTORPYK effectively formalizes the PIK3CA wild-type treatment space, addressing a previously underserved segment of the HR+/HER2- breast cancer market. By demonstrating that broad-spectrum PI3K/mTOR inhibition can offer a viable therapeutic path for patients who have progressed on CDK4/6 therapy, Celcuity has established a new standard in the treatment algorithm.
This development suggests a broader trend in pharmaceutical R&D, where future clinical strategies will likely increasingly prioritize biomarker-defined therapeutic classes and multi-pathway inhibition paired with existing endocrine backbones to secure both regulatory approval and competitive market positioning.
Comments